The EMPOWER-Lung 1 trial compared the use of cemiplimab alone to the choice of chemotherapy made by the investigators in patients who were newly diagnosed with advanced NSCLC and tumor PD-L1 expression of at least 50%, along with no EGFR mutations or ALK or ROS1 fusions. Here, EGFR is linked to non-small cell lung carcinoma.